

Journal of Antimicrobial Chemotherapy (2008) **61**, 332–340
doi:10.1093/jac/dkm491
Advance Access publication 3 January 2008

JAC

***In vitro* cell compatibility and antibacterial activity of microencapsulated doxycycline designed for improved localized therapy of septic arthritis**

M. Christina Haerdi-Landerer^{1*}, Maja M. Suter², Adrian Steiner³, Max M. Wittenbrink⁴,
Andrea Pickl⁵ and Bruno A. Gander⁵

¹AO Research Institute, 7270 Davos-Platz, Switzerland; ²Institute of Animal Pathology, Vetsuisse-Faculty, 3001 Berne, Switzerland; ³Clinic for Ruminants, Vetsuisse-Faculty, 3001 Berne, Switzerland; ⁴Institute of Veterinary Bacteriology, Vetsuisse-Faculty, 8057 Zurich, Switzerland; ⁵Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland

Received 22 June 2007; returned 16 August 2007; revised 25 September 2007; accepted 23 November 2007

Objectives: For the treatment of septic arthritis in large animals, the local application of antibiotics as a slow release system may be an appropriate means to reach high local bioactivity and low systemic side effects and drug residues. In this study, doxycycline microspheres were developed and tested *in vitro* for their drug-release properties, suitability for intra-articular application and antimicrobial activity.

Methods: The development of a slow release system was achieved by microencapsulation of the drug into poly(lactide-co-glycolide) microspheres by a novel ultrasonic atomization method. Drug elution was evaluated from microspheres dispersed in elution medium at pre-defined time points by HPLC. Joint-tissue compatibility was tested on cultured bovine synoviocytes by evaluating the expression of pro-inflammatory cytokine mRNA and the production of nitric oxide (NO). Finally, the antimicrobial activity of the released antibiotic was assessed with Gram-negative and Gram-positive bacteria exposed to release medium sampled at days 1, 7 and 12 after microsphere suspension.

Results: An adequate size of the microspheres, sufficient stabilization of doxycycline in aqueous environment and drug release (25 mg microspheres in 4 mL medium) above MIC for bacteria usually isolated in bovine and equine joints were obtained over 15 days. Although the cytokine mRNA expression reflected the excellent tissue compatibility, the results with NO yielded contradictory results. Antimicrobial tests of the release medium proved to match perfectly the activity of non-encapsulated, free doxycycline as reported in the literature.

Conclusions: The newly developed doxycycline delivery system achieved the target specifications and is ready for *in vivo* testing.

Keywords: septic arthritis, microspheres, *in vitro* toxicity, antimicrobial activity

Introduction

Treatment of septic arthritis in large animals is demanding and prognosis still guarded.^{1–3} Besides surgical interventions, the immediate onset of antibiotic therapy is mandatory.⁴ Local application of antibiotics has the advantage of providing high drug concentrations at the site of infection while keeping the systemic concentrations low, which results in less systemic side

effects and lower drug residues in muscular tissues.^{5,6} Disadvantages of local drug application are the risk of joint tissue toxicity and superinfections following repeated arthrocenteses.^{4,7}

Attempts to overcome the problems of repeated local drug administration have primarily focused on using slow release formulations of antibiotics.⁸ Two slow release antibiotic products are commercially available for human treatment in Switzerland.

*Corresponding author. Tel: +4144 6326944; Fax: +4144 6321128; E-mail: christina-haerdi@ethz.ch

Doxycycline microspheres tested for septic arthritis therapy

The first consists of gentamicin-containing poly(methylmethacrylate) (PMMA) beads (Septopal®-Ketten, Biomet Orthopaedics, Ried b.Kerzers, Switzerland), which can be implanted into infected wounds, septic joints and in the vicinity of fractured bones. After healing or exhaustion of the antibiotic activity, the beads have to be removed surgically.^{9–11} The second marketed formulation is a gentamicin-soaked sponge made from bovine collagen (Garamycin® Schwamm, Essex Chemie, Luzern, Switzerland). The collagen sponge is biore-sorbable and does, therefore, not require a second surgical intervention. Furthermore, it diminishes the risk of developing a resistant flora as described for the PMMA beads.^{3,12,13} Conversely, the collagen sponge affords shorter periods of drug release than the PMMA beads^{14,15} and possesses the risk of propagating transmissible spongiform encephalitis.

Investigational studies have considered a variety of antibiotics and slow release formulations, many of which were based on PMMA or on biodegradable poly(lactide) or poly(lactide-co-glycolide) (PLGA).^{16–19} The most commonly used antibiotic in these studies was gentamicin. Gentamicin covers a broad antibiotic spectrum including bacterial pathogens often isolated from equine joints. However, it is also known for its irritating activity by inducing a mild and transient synovitis⁷ and its relative inefficiency against anaerobic bacteria often isolated from bovine joints.^{20–22} A good alternative to gentamicin for slow release formulations designed for the treatment of infected joints is doxycycline hyclate. Introduced into human pharmacotherapy in 1967,²³ it has proven its antibiotic efficacy against most of the pathogenic bacteria isolated from inflamed joints of horses and cattle.^{23–25} However, resistance to tetracyclines is a worldwide problem. It is due to either decreased intracellular antibiotic accumulation caused by inhibition of drug import into the cell or increased antibiotic efflux, or to a mechanism to protect cellular ribosomes. Generally, there is cross-bacterial resistance among tetracycline and doxycycline, but there are several exceptions described (e.g. *Bacteroides fragilis*²⁶ and *Streptococcus pneumoniae*²³). When focusing on bacteria relevant for septic arthritis, a general overview about the susceptibility of bacterial isolates from horses in The Netherlands²⁴ reports some resistance of *Escherichia coli* and *Klebsiella* spp., but none of the tested *Streptococci* and *Staphylococci* spp. and *Actinobacillus equuli* showed MICs above 2 mg/L. All *Staphylococcus aureus* isolates from cattle in Brazil were also susceptible to doxycycline, whereas 7 of 46 strains were resistant to tetracycline.²⁷

Doxycycline has been reported to be chondroprotective both *in vitro*^{28–30} and in human clinical studies.^{31,32} Our own experiments revealed a very good local tissue compatibility of doxycycline in bovine joints.³³

Further critical issues relevant for developing and using slow release antibiotic formulations are the stability of the antibiotic in the formulation during the entire release period and the ease of localized administration, e.g. in infected joints of animals. Readily administrable slow release formulations are, for example, biodegradable microspheres made of PLGA. PLGA microspheres can be administered with a conventional syringe and needle. Several hormone-containing PLGA products are on the market for human use to systemically treat different forms of cancer. When considering the stability issue, many antibiotics will not be useful for slow release as they degrade quickly, i.e. within a few hours or days. Examples of unstable antibiotics include erythromycin, penicillins and cephalosporins, which

hydrolyse quickly upon contact with aqueous media. Tetracyclines, although not susceptible to hydrolysis, readily undergo oxidation and epimerization. Nevertheless, doxycycline is one of the most stable tetracycline group members and has, in our preliminary experiments, promised to be a good candidate for slow release formulations.³⁴ The feasibility of microencapsulating tetracycline compounds into PLGA has been demonstrated for minocycline used to treat periodontitis in man.³⁵

In the present study, we developed slow release PLGA microspheres for the delivery of doxycycline as improved treatment of infected joints of horses and cattle. The formulations were tested for the duration of doxycycline release, doxycycline stability, *in vitro* toxicity and *in vitro* antimicrobial activity.

Materials and methods

Doxycycline microencapsulation into PLGA microspheres

Doxycycline hyclate (Ph. Eur.; Spirig, Egerkingen, Switzerland) was microencapsulated into PLGA 50:50 (PLGA 50:50, Resomer® 502 H, Boehringer-Ingelheim, Ingelheim, Germany) at 10% nominal drug loading. During processing and storage, all materials were protected from light and oxygen. For a 3 g batch, 300 mg doxycycline was dissolved in 3 mL of methanol, and this solution was added slowly to a solution of 2.7 g of PLGA dissolved in 27 mL of acetone. The clear and slightly yellowish doxycycline/PLGA solution was atomized at a rate of 30 mL/h through an ultrasonic spray-head (US1, Lechler, Metzingen, Germany) into 500 mL of octamethylcyclotetrasiloxane (OMCTS; Abil K-4, Goldschmidt, Essen, Germany) under moderate stirring. At the end of atomization, the slurry was exposed to a slightly reduced pressure (400 mbar) for 3 h to eliminate further the solvents and harden the microspheres. The microsphere dispersion in OMCTS was filtered through a 0.2 µm regenerated cellulose filter (Schleicher & Schuell, Dassel, Germany), washed three times with 20 mL of cyclohexane and dried overnight at 30°C and 20 mbar. For storage, the microspheres were filled into brown glass vials, purged with argon and kept at 4°C in the dark. A portion of the microspheres was also subjected to γ-irradiation (25 kGy, Studer Hard, Däniken, Switzerland) to test potential instability and degradation during sterilization.

Determination of microsphere size and doxycycline loading

Particle size was analysed by laser light diffraction (Mastersizer X, Malvern, UK). The doxycycline content in the microspheres was determined by dissolving 10 mg of microspheres (accurately weighed) in 8.0 mL of acetonitrile and completing the solution with 2.0 mL of water. The filtered solution (0.45 µm cellulose acetate filter) was analysed by HPLC,³⁶ using an EZCHROM Elite Hitachi (Hitachi, VWR International, Dietikon, Switzerland) with a UV-VIS detector L-2420, an autosampler L-2200 and a pump L-2130. Separation was performed on a C₈-Phenomenex Luna column (5 µm, 250 × 4.6 mm; Brechbühler, Schlieren, Switzerland) under isocratic conditions using as mobile phase a degassed mixture of acetonitrile/water/perchloric acid (26:74:0.25, by vol.) adjusted to pH 2.5 with

5 M sodium hydroxide. The flow rate was 1.0 mL/min, and doxycycline was detected at 350 nm.

In vitro doxycycline release testing

Microspheres (20 mg, accurately weighed) were filled in 4.5 mL amber borosilicate screw-top vials (BGB Analytik, Adliswil, Switzerland) and dispersed in 4.0 mL of release medium. The release medium consisted of a 0.1 M citrate buffer of pH 5.0, supplemented with 0.01% (w/w) sodium azide, 0.01% (w/w) poloxamer 188 and 0.01% sodium EDTA. The vials were installed in a drum rotating at 3 rpm and placed at 37°C. At regular time intervals, the entire release medium of four vials was withdrawn and analysed by HPLC, as described in the previous section. The remaining polymeric pellets were dried under vacuum overnight, and the non-released doxycycline extracted and analysed by HPLC as described in the previous section.

In vitro toxicity testing of doxycycline and doxycycline-loaded microspheres on cultured bovine synoviocytes

Establishment of bovine synovial cell cultures. Synovial membranes of four calves and two cows (aged between 6 months and 4 years), who were routinely slaughtered in a local abattoir, were harvested aseptically from fetlock (metacarpophalangeal) joint. A separate culture was prepared for each animal. After two washes in saline, the membranes were cut into small pieces of ~1 mm², placed into the inner part of a two-compartment digestion chamber,³⁷ pre-treated with 0.2% trypsin at 37°C for 30 min and subsequently digested enzymatically with 0.2% collagenase for 2 h at 37°C under constant movement. The cells were collected from the outer compartment of the digestion chamber, washed three times with Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen, Basel, Switzerland) containing 10% fetal bovine serum and subsequently seeded in six-well plates (Falcon Companion Plate 6 Wells, Milian, Meyrin, Switzerland) at 100 000 cells per well. For maintenance, the cells were cultured at 95% humidity, 5% CO₂ and 37°C for 7–8 days until confluence, with the medium being changed every 2–3 days.

Cytotoxicity testing. Preliminary tests were performed to evaluate the cytotoxicity of bacterial lipopolysaccharide (LPS) using different concentrations and incubating over different periods of time. Incubation time and concentrations were chosen to prevent enhanced cell death. Cell numbers were assessed using a cell viability test based on cleavage of tetrazolium salt (Cell Proliferation Reagent WST-1, Roche Diagnostics, Mannheim Germany). β -Actin-

messenger RNA levels proved to correlate significantly ($P < 0.001$) with the viability test and were thus chosen for normalization.

For toxicity experiments, the cells were vigorously washed with phosphate-buffered saline (PBS) containing 0.2 g/L KCl, 1.0 g/L NaHCO₃ and 1 g/L glucose monohydrate and treated with (i) plain DMEM (negative control), (ii) 100 mg/L LPS (Sigma-Aldrich, Buchs SG, Switzerland) (positive control), (iii) 1 mg/mL doxycycline in solution (Vibravenoes[®], Pfizer, Zurich Switzerland), (iv) 0.2 mg/mL microspheres (low-dose microspheres; 20 μ g/mL doxycycline), and (v) 5 mg/mL microspheres (high-dose microspheres; 500 μ g/mL doxycycline). For incubation, all test materials (LPS, doxycycline, and microspheres) were dissolved or suspended in DMEM; incubation lasted for 4 or 24 h. With the high-dose microspheres, the cells were completely and firmly covered with the microspheres, which compromised the further separation and lysis of the cells. Hence, an insert (Falcon 0.4 μ m HD Inserts, Milian) was used for the high-dose microspheres to allow separation of microspheres and cells and to facilitate the collection of the cells. The supernatant of all cell samples was collected and kept at –80°C until further use. The cells were lysed in TRI Reagent[®] (Molecular Research Center, Cincinnati, OH, USA), their RNA extracted following the manufacturer's instructions and the extracts kept at –80°C until further processing. Each test was performed in triplicate.

The differently treated synoviocytes were analysed for the production of interleukin (IL)-1 β , IL-6 and tumour necrosis factor (TNF)- α mRNA by RT-PCR. β -Actin was used as the housekeeping gene. The primers and probes (Table 1; all from Microsynth, Balgach, Switzerland) were designed on the basis of the GenBank database and with the help of the Primer Express Oligo Design software version 1.5 (Applied Biosystems, Foster City, CA, USA). The probes were designed to contain an exon–exon junction overlapping sequence to exclude the measuring of genomic DNA and they were labelled with the reporter molecule 6-carboxyfluorescein (FAM) at the 5' ends and with the quencher molecule 6-carboxy-*N,N,N'*, *N'*-tetramethylrhodamine (TAMRA) at the 3' ends. As a reference, cDNA from stimulated bovine macrophages (kindly provided by Prof. T. Jungi, Institute of Immunology, Vetsuisse Faculty, University of Berne, Berne, Switzerland) was used for assessing the efficiency of multiplication and calculating the mRNA content (eff^{-x}).

Reverse transcription of 1 μ g of RNA per cell sample was performed with TaqMan reverse transcription reagents (Applied Biosystems) using random hexamer primers. PCR was carried

Table 1. Primers and probes used for real-time RT-PCR of cytokines and the corresponding multiplication efficiency factors

Gene	Forward primer	Reverse primer	Probe	Efficiency
IL-1 β	5'-TTA CTA CAG TGA CGA GAA TGA GCT GTT	5'-GGT CCA GGT GTT GGA TGC A	5'-CTC TTC ATC TGT TTA GGG TCA TCA GCC TCA A	1.724
IL-6	5'-ACT GGC AGA AAA TAA GCT GAA TCT TC	5'-TGA TCA AGC AAA TCG CCT GAT	5'-AAC CCA GAT TGG AAG CAT CCG TCC TTT	1.788
TNF	5'-CCT CTT CTC AAG CCT CAA GTA ACA A	5'-GAG CTG CCC CGG AGA GTT	5'-ATG TCG GCT ACA ACG TGG GCT ACC G	1.84
β -Actin	5'-CGG CAC CAG GGC GTA AT	5'-TCT CCA TGT CGT CCC AGT TG	5'-AGC AAG AGA GGC ATC CTG ACC CTC AAG T	1.79

Doxycycline microspheres tested for septic arthritis therapy

out in 24 μL reactions with 900 nM of each primer, 250 nM of labelled probe and Universal PCR master mix (Applied Biosystems) under standard thermal conditions with an AB 7500 Real Time PCR System (Applied Biosystems).

The nitric oxide (NO) release from the synoviocytes incubated during 24 h with doxycycline solution, doxycycline-loaded microspheres and control samples was examined using the Total NO/Nitrite/Nitrate Assay (R&D Systems, Bühlmann Laboratories, Schönenbuch, Switzerland), which is based on the Griess reaction. The amounts of NO were normalized to the amount of β -actin mRNA.

Contents of mRNA and NO were expressed relative to the amounts of the negative control (DMEM) at 4 h (mRNA) and 24 h (NO). Statistical data analysis was performed using the Number Cruncher Statistical System (Kaysville, UT, USA). Groups were compared using one-way analysis of variance (ANOVA), and the P value was set at 0.05.

In vitro antimicrobial activity testing of doxycycline released from microspheres

Release test medium from six samples, each of non-irradiated and γ -irradiated doxycycline-loaded microsphere preparations (see the section on Doxycycline microencapsulation into PLGA microspheres), was used for the assessment of the antimicrobial activity of doxycycline released after 1, 7 and 12 days. The day before the sampling of the release test medium for microbial testing, the entire release medium was discarded and replaced by fresh release medium (see the section on *In vitro* doxycycline release testing; medium without sodium azide). This procedure eliminated any doxycycline-degradation products developing in the release medium over time and considered only the amount of doxycycline released within 24 h at the above indicated time points. Samples were stored at -20°C until further use. Before performing the antibacterial tests, the doxycycline concentration was assessed for every sample with the HPLC analysis (see the section on Determination of microsphere size and doxycycline loading).

The *in vitro* antibacterial activity of the released doxycycline against *S. aureus* ATCC 25923 and *E. coli* ATCC 25922 was determined using the microdilution method in cation-adjusted Mueller–Hinton broth (CAMBH), according to the CLSI guidelines.³⁸ Doxycycline hydrochloride solutions in citrate buffer (concentrations from 64 to 0.125 mg/L) served as reference dilutions and plain elution buffer as negative control. Release test samples from microspheres were pre-diluted or used undiluted according to the results from HPLC measurements. Every sample was subjected to serial dilutions in order to evaluate the individual MIC as calculated from the number of dilution steps. Bacterial cultures were expanded in CAMBH at 37°C for 4–6 h. Inocula were adjusted to 1×10^6 bacteria/mL nephelometrically, using standardization curves determined in earlier studies. Microtitre plates (U-shaped bottom; Greiner, Frickenhausen, Germany) were loaded with 50 μL of serially diluted release testing samples and controls. To each well, 50 μL of standard inoculum was added and incubated for 24 h. The MIC was read as the lowest concentration without visible growth.

Statistical analysis

The data were statistically analysed by ANOVA and Bonferroni *post hoc* test. P values less than 0.05 were considered significant.

Results

Yield, size and doxycycline content of the microspheres

The product yield was in the range of 70% to 75%, and the volume weighted particle size range was between 15 and 120 μm with a mean diameter of 35 μm . The doxycycline content in the non-irradiated and γ -irradiated microspheres amounted to 82 and 77 $\mu\text{g}/\text{mg}$ microspheres, respectively, corresponding to an encapsulation efficiency of more than 80%. No differences were observed in the HPLC chromatograms between non-irradiated and irradiated samples in terms of additional peaks, thus excluding potential doxycycline degradation




Figure 1. Doxycycline release profiles from non-irradiated (open circles) and γ -irradiated (25 kGy) (filled circles) PLGA 50:50 microspheres. (a) Doxycycline release directly measured in the test medium. (b) Doxycycline release determined as the difference between the primary doxycycline content of microspheres and the amount of non-released doxycycline that remained in the polymeric pellet at the indicated time points.

products. Therefore, in microencapsulated form, doxycycline appeared to remain stable during γ -irradiation.

In vitro release of doxycycline

To assess the stability of doxycycline at 37°C over prolonged periods of time, the amount of released doxycycline was assessed in two ways: by analysing doxycycline in the release medium (Figure 1a) and by determining the amount of non-released doxycycline in the remaining polymeric mass (Figure 1b). Both analytical methods revealed a triphasic release profile, lasting ~15 days, and no significant differences were found between non-irradiated and γ -irradiated microspheres (Figure 1).

When doxycycline was analysed in the release medium, the triphasic release profile consisted of an initial burst amounting to ~30 $\mu\text{g}/\text{mg}$ microspheres, a period of very little doxycycline release that lasted ~3 days, and a final phase of almost constant release of an additional ~30 $\mu\text{g}/\text{mg}$ microspheres between days 4 and 15 (Figure 1a). After day 15, a slight decrease suggested some degradation of doxycycline in the release medium, which was confirmed by the appearance of an additional elution peak in the HPLC chromatograms (R. Alder and A. Pickl, data not shown). Thus, ~20 μg doxycycline/mg microspheres degraded in the release medium within 15 days of incubation.

Calculating from the amount of non-released doxycycline in the remaining polymeric mass, both the burst (~58 $\mu\text{g}/\text{mg}$ microspheres) and the total amount released (~98 $\mu\text{g}/\text{mg}$ microspheres) were higher (Figure 1b), and there was no apparent loss of material after completion on day 15. The apparently excessive total amount of doxycycline released (~98 $\mu\text{g}/\text{mg}$ microspheres versus 82 $\mu\text{g}/\text{mg}$ microspheres doxycycline loading) must be ascribed to small yet cumulative quantities of doxycycline remaining in the vials (remaining release medium, vial wall, adsorbed on the surface of polymer pellet) each time the release medium was withdrawn; these residual amounts of doxycycline in the vial were added to the amount of non-released doxycycline, as the remaining polymeric material was dissolved in the vial itself.

In vitro toxicity of doxycycline and doxycycline-loaded microspheres on cultured bovine synoviocytes

The synoviocytes incubated for 4 h with doxycycline or doxycycline-loaded microspheres expressed similar amounts of cytokine-specific mRNA to those incubated with plain medium, but significantly less than the positive control cells stimulated with LPS ($P < 0.01$) (Figure 2). When normalizing the mRNA levels of the treated cells against the negative control cells (incubated with plain medium), the IL-1 β -specific mRNA was increased by factors of 1.2 (plain doxycycline), 1.5 (low-dose microspheres), 1.8 (high-dose microspheres) and 11.0 (positive LPS control) (Figure 2a). For the IL-6-specific mRNA (Figure 2b), the relative changes of expression level over that observed with the negative control cells were 3.4 with plain doxycycline, 1.0 with the low-dose microspheres, 0.7 with the high-dose microspheres and 33.2 with the LPS control. For the TNF- α -specific mRNA (Figure 2c), the relative changes were 2.0 with the plain doxycycline, 1.8 with the low-dose microspheres, 2.9 with the high-dose microspheres and 39.3 with the positive control.




Figure 2. Relative mRNA content of (a) IL-1 β , (b) IL-6 and (c) TNF- α produced by cells stimulated for 4 h with 1 mg/mL plain doxycycline (DOX), 5 mg/mL microspheres (500 $\mu\text{g}/\text{mL}$ doxycycline) (MS high) and 0.2 mg/mL microspheres (20 $\mu\text{g}/\text{mL}$ doxycycline) (MS low). The negative control (NEG) was performed with the plain culture medium and the positive control (POS) was performed with the medium containing 100 $\mu\text{g}/\text{mL}$ LPS. \times , outlier.

After 24 h of incubation, the mRNA expression levels changed variably depending on the treatment. When compared with the negative control at 24 h, the IL-1 β -specific mRNA (C. Haerdi-Landerer, data not shown) did not change with plain doxycycline, but increased by a factor of 29.0 in the positive control and decreased by factors of 0.7 and 0.1 with the low-dose and high-dose microspheres, respectively. For the non-stimulated cells, the increase in IL-1 β mRNA expression between 4 and 24 h was 1.3-fold. The IL-6 mRNA (C. Haerdi-Landerer, data not shown) increased by factors of 13.1 (plain doxycycline), 239.8 (positive control) and 1.9 (high-dose microspheres), but decreased slightly (by a factor of 0.9) with the low-dose microspheres when compared with the negative control at 24 h. For the negative control cells, the IL-6 mRNA expression decreased by the factor of 0.34 between 4 and 24 h. Finally, the TNF- α mRNA levels (Figure 3) at 24 h were increased by factors of 10.4 (positive control), 3.6 (plain doxycycline), 1.03 (low-dose microspheres), and 7.8 (high-dose

Doxycycline microspheres tested for septic arthritis therapy




Figure 3. Relative content of TNF- α mRNA of cells stimulated for 4 h (empty boxes) and 24 h (grey boxes) with 1 mg/mL plain doxycycline (DOX), 5 mg/mL microspheres (500 μ g/mL doxycycline) (MS high) and 0.2 mg/mL microspheres (20 μ g/mL doxycycline) (MS low). The negative control (NEG) was performed with the plain culture medium and the positive control (POS) was performed with the medium containing 100 μ g/mL LPS. \times , outlier.

microspheres) in comparison with the negative control cells. At this time point, only the TNF- α mRNA content of the synovocytes incubated with the low-dose microspheres was significantly below the value of the positive control cells ($P = 0.0023$) (Figure 3). In the negative control cells, the TNF- α mRNA expression increased by a factor of 3.6 between 4 and 24 h.

NO production by the synovocytes appeared to be increased in the positive control and the high-dose microsphere groups when compared with the negative control and the low-dose microsphere groups. Nonetheless, the statistical differences were only weak in the ANOVA ($P = 0.048$), and no significant difference was observed between any of the groups when using the Bonferroni *post hoc* test (Figure 4). When the amounts of NO




Figure 4. Relative content of NO in the cell supernatant after 24 h of stimulation with 1 mg/mL plain doxycycline (DOX), 5 mg/mL microspheres (500 μ g/mL doxycycline) (MS high) and 0.2 mg/mL microspheres (20 μ g/mL doxycycline) (MS low). The negative control (NEG) was performed with plain culture medium and the positive control (POS) was performed with medium containing 100 μ g/mL LPS. \times , outlier.

were normalized to the amount of β -actin mRNA isolated from the cells of the same well, the NO contents were increased, relative to the negative control cells, by factors of 26.4 for the positive control, 3.4 for the plain doxycycline, and 10.5 and 119.4 for the low-dose and high-dose microsphere groups, respectively.

In vitro antimicrobial activity of doxycycline released from microspheres

HPLC measurements of doxycycline in release media of microspheres revealed mean values of 200.5 ± 8.2 mg/L for day 1, 14.1 ± 5.2 mg/L for day 7 and 22.4 ± 1.1 mg/L for day 12. Thus, day 1 media were diluted 1:9 before starting serial dilution. With *E. coli* ATCC 25922, ranges of MICs for doxycycline in the release medium were 0.6–1.26 mg/L for day 1 samples, 0.41–0.92 mg/L for day 7 samples and 0.66–0.75 mg/L for day 12 samples. With *S. aureus* ATCC 25923, the MIC value ranges were 0.15–0.32 mg/L for day 1, 0.15–0.46 mg/L for day 7 and 0.16–0.19 mg/L for day 12. Thus, the MIC values of released doxycycline against both bacterial strains were kept within the limits in terms of strain-specific CLSI doxycycline reference MIC values (*E. coli*: 0.5–2.0 and *S. aureus*: 0.12–0.5). No differences were found between the three different time points or between samples from γ -irradiated and non-irradiated microspheres. Overall, the antimicrobial activity of doxycycline released from microspheres after 1, 7 and 12 days generally coincided with the original substance.

Discussion

The aim of this study was to produce doxycycline-containing microspheres at high yield, with good encapsulation efficiency, particle sizes above the threshold for uptake by phagocytes, controlled antibiotic release over ~ 14 days, low inflammatory reaction and intact antibiotic activity. Further, the controlled release and bioactivity of the formulation should remain unaltered upon sterilization by γ -irradiation. These specifications, defined in view of subsequently using the delivery system for the localized and prolonged treatment of septic arthritis in large animals, were all successfully met in this study.

The microencapsulation of antibiotics generally faces some of the following hurdles: drug degradation, modest encapsulation efficiency, alteration by sterilization or scaling-up difficulties. Different methods for microencapsulation of antibiotics have been described.^{35,39,40} Spray-drying was excluded, because it is known to yield, at least with laboratory spray-dryers, small particles (diameters of 0.1–10 μ m) that are highly susceptible to phagocytosis, especially in inflamed tissue. The solvent extraction/evaporation methods generally yield modest encapsulation efficiency with highly water-soluble drugs, besides being difficult to scale up. Indeed, our own preliminary experiments confirmed a very low encapsulation efficiency of doxycycline in PLGA 50:50 microspheres when using a microextrusion-based solvent extraction method (S. Fischer and B. Gander, unpublished results). The method developed in this study was tailored to the particular materials used and the pre-defined aforementioned specifications. The ultrasonic atomization of the organic doxycycline–PLGA solution into the non-solvent OMCTS

produced the desired particle size range at a high yield. The absence of water in the process was most favourable for the high encapsulation efficiency and preservation of the doxycycline stability. Furthermore, the method can be readily scaled-up and transferred to an industrial setting.

Drug stability is definitely the first prerequisite for prolonged release over the desired time interval of 10–15 days. Many antibiotics such as penicillins, cephalosporins and erythromycin are sensitive to humidity and hydrolyse in the presence of water. These drugs are obviously unsuitable for prolonged release from PLGA microspheres, which release entrapped drugs by diffusion upon hydration of the particles in water and hydrolytic degradation of the polyester. Our own attempts to microencapsulate a cephalosporin compound into PLGA failed badly, because we were unable to slow down sufficiently the hydrolysis of the drug (S. Fischer and B. Gander, unpublished results). For the intended therapeutic use, a good alternative to cephalosporins are the tetracyclines. Tetracycline and its analogues do not undergo hydrolysis, but are susceptible to photolysis, epimerization and isomerization.^{34,36} Doxycycline hyclate was selected for our work, because it is one of the most stable tetracycline analogues and it is already successfully used in drug delivery systems (DOXY[®], Vivadent Ivoclar, Schaan, Liechtenstein; Atridox[®], CollaGenex Pharmaceuticals, Newtown, PA, USA) for periodontal application. For developing a suitable *in vitro* release test medium for the doxycycline-loaded microspheres, preliminary stability experiments were conducted in different buffer systems and by the addition of putative stabilizers. Here, an enhanced doxycycline stability was noticed in pure water and citrate buffer of pH 5.0 over PBS of pH 7.4 (20% versus 30% degradation within 7 days at 37°C). A further improvement was achieved by adding sodium EDTA (0.01%) to the citrate buffer (12% degradation within 7 days at 37°C) (A. Pickl and B. Gander, data not shown).

The *in vitro* doxycycline release from the PLGA 50:50 microspheres in the optimized medium lasted for 14 days. The initial burst was expected for the highly water-soluble antibiotic and should be appropriate to reach an immediate biologically active antibiotic concentration. The apparent total release was, however, substantially lower when doxycycline was analysed in the release medium when estimated from the amount of non-released drug (Figure 1a versus 1b). This demonstrates good protection of doxycycline within the PLGA microspheres against epimerization and oxidation. Furthermore, γ -irradiation did not significantly degrade doxycycline within the microspheres or alter the *in vitro* release profile. This negligible effect is especially important in view of developing a product for parenteral application; it was, however, surprising because many, if not most, of the published studies on the γ -irradiation of PLGA-encapsulated drugs reveal significant drug degradation and accelerated drug release after irradiation of the microspheres.^{41,42} We may speculate that the absence of water during microencapsulation yielded a product with very low residual humidity. Therefore, the amount of H[•] and OH[•] radicals formed during irradiation may have been extremely low, thus limiting substantially any subsequent radiolysis of drug or polymer. Importantly, the feasibility of γ -irradiation of the doxycycline-loaded microspheres facilitates greatly the production of controlled release doxycycline for improving the therapy of septic arthritis in large animals.

As an endeavour to reduce animal tests, cultured synovio-cytes from several species have been used for tissue compatibility testing of drugs.^{43,44} In joint tissues, inflammation and matrix degradation have been strongly associated with increased levels of the cytokines IL-1 β , IL-6 and TNF- α . Thus, these markers are often used as parameters for the evaluation of joint irritation and inflammation.^{43,45,46} In our study, we noticed significant differences of cytokine mRNA expression in bovine synovial cells treated with and without bacterial LPS, which demonstrates the suitability of this test system for evaluating the *in vitro* cell compatibility of the developed delivery system. The minimal changes of cytokine expression observed with the doxycycline-loaded microspheres, when compared with the negative control, suggest a very good tissue compatibility of the microsphere formulation. The apparent impact of the duration of incubation on the TNF- α expression was surprising. A nearly 4-fold increase in TNF- α mRNA expression was observed from 4 to 24 h of incubation in the negative control cells. This must be assigned to the absence of fetal bovine serum. Furthermore, the starved cells were less tolerant to the exposure to plain doxycycline or the high-dose microspheres.

Another marker of tissue irritation and inflammation is NO. NO production by cultured synoviocytes has been used as a parameter for tissue irritation in horses,⁴⁷ humans⁴⁸ and rabbits.⁴⁹ However, regulation of NO synthases differs between different species and also between different tissues.^{50,51} Nevertheless, the increased NO content in the supernatant of the cells stimulated with the doxycycline-containing microspheres has to be taken into account when interpreting the overall reaction of cultured synoviocytes to the delivery system. NO has been reported to act as inflammatory mediator, but its action within the cascade is contradictory, exerting protective as well as pro-inflammatory and catabolic activities on the cartilaginous matrix.^{52,53} Therefore, conclusive answers will only be obtained through *in vivo* experiments.

The antimicrobial tests proved the biological activity of the doxycycline released from both the non-irradiated and γ -irradiated microspheres. The MICs of the doxycycline released from the microspheres conformed exactly to the values reported in the literature, i.e. 0.5–2.0 mg/L for *E. coli* and 0.12–0.5 mg/L for *S. aureus*.³⁸

Acknowledgements

We acknowledge Studer Hard (Dänikon, Switzerland) for the γ -irradiation of the microspheres. We also thank the tissue engineering group of the AO Research Institute (Davos, Switzerland), namely, Dr Sibylle Grad, for help with the PCR technique, and Ruth Alder and Stefan Fischer, Institute of Pharmaceutical Sciences, ETH Zurich (Switzerland), for technical support.

Funding

This study was supported by grants from the Swiss Federal Innovation Promotion Agency CTI (Berne, Switzerland) and Dr E. Graeb AG, Veterinary Products (Berne, Switzerland).

Transparency declarations

M. C. H.-L. was funded by the CTI grant. All other authors are independent of this funding body. The sponsors of the study had no role in study design, data collection, data interpretation or writing the report.

References

1. Lapointe JM, Laverty S, Lavoie JP. Septic arthritis in 15 standardbred racehorses after intra-articular injection. *Equine Vet J* 1992; **24**: 430–4.
2. Steel CM, Hunt AR, Adams PL *et al.* Factors associated with prognosis for survival and athletic use in foals with septic arthritis: 93 cases (1987–1994). *J Am Vet Med Assoc* 1999; **215**: 973–7.
3. Steiner A, Hirsbrunner G, Miserez R *et al.* Arthroscopic lavage and implantation of gentamicin-impregnated collagen sponges for treatment of chronic septic arthritis in cattle. *Vet Comp Orthop Traumatol* 1999; **12**: 64–9.
4. McIlwraith CW. Treatment of infectious arthritis. *Vet Clin North Am Large Anim Pract* 1983; **5**: 363–79.
5. Hirsbrunner G, Steiner A. Treatment of infectious arthritis of the radiocarpal joint of cattle with gentamicin-impregnated collagen sponges. *Vet Rec* 1998; **142**: 399–402.
6. Lloyd KC, Stover SM, Pascoe JR *et al.* Synovial fluid pH, cytologic characteristics, and gentamicin concentration after intra-articular administration of the drug in an experimental model of infectious arthritis in horses. *Am J Vet Res* 1990; **51**: 1363–9.
7. Stover SM, Pool RR. Effect of intra-articular gentamicin sulfate on normal equine synovial membrane. *Am J Vet Res* 1985; **46**: 2485–91.
8. Sun Y, Scruggs DW, Peng Y *et al.* Issues and challenges in developing long-acting veterinary antibiotic formulations. *Adv Drug Deliv Rev* 2004; **56**: 1481–96.
9. Butson RJ, Schramme MC, Garlick MH *et al.* Treatment of intra-synovial infection with gentamicin-impregnated polymethylmethacrylate beads. *Vet Rec* 1996; **138**: 460–4.
10. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. *Drugs* 2000; **59**: 1223–32.
11. Ostermann PA, Seligson D, Henry SL. Local antibiotic therapy for severe open fractures. A review of 1085 consecutive cases. *J Bone Joint Surg Br* 1995; **77**: 93–7.
12. Stemberger A, Grimm H, Bader F *et al.* Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. *Eur J Surg Suppl* 1997; **17**: 26.
13. Summerhays GE. Treatment of traumatically induced synovial sepsis in horses with gentamicin-impregnated collagen sponges. *Vet Rec* 2000; **147**: 184–8.
14. Ivester KM, Adams SB, Moore GE *et al.* Gentamicin concentrations in synovial fluid obtained from the tarsocrural joints of horses after implantation of gentamicin-impregnated collagen sponges. *Am J Vet Res* 2006; **67**: 1519–26.
15. Wachol-Drewek Z, Pfeiffer M, Scholl E. Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. *Biomaterials* 1996; **17**: 1733–8.
16. Ethell MT, Bennett RA, Brown MP *et al.* *In vitro* elution of gentamicin, amikacin, and ceftiofur from polymethylmethacrylate and hydroxyapatite cement. *Vet Surg* 2000; **29**: 375–82.
17. Hoff SF, Fitzgerald RH Jr, Kelly PJ. The depot administration of penicillin G and gentamicin in acrylic bone cement. *J Bone Joint Surg Am* 1981; **63**: 798–804.
18. Garvin KL, Myjano JA, Robinson D *et al.* Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. A canine model. *J Bone Joint Surg Am* 1994; **76**: 1500–6.
19. Alonge TO, Fashina AN. Ceftriaxone-PMMA beads—a slow release preparation? *Int J Clin Pract* 2000; **54**: 353–5.
20. Verschooten F, Vermeiren D, Devriese L. Bone infection in the bovine appendicular skeleton: a clinical, radiographic, and experimental study. *Vet Radiol Ultrasound* 2000; **41**: 250–60.
21. Van Pelt RW. Infectious arthritis in cattle caused by *Corynebacterium pyogenes*. *J Am Vet Med Assoc* 1970; **156**: 457–65.
22. Bailey JV. Bovine arthritides. Classification, diagnosis, prognosis, and treatment. *Vet Clin North Am Food Anim Pract* 1985; **1**: 39–51.
23. Joshi N, Miller DQ. Doxycycline revisited. *Arch Intern Med* 1997; **157**: 1421–8.
24. Ensink JM, van Klingeren B, Houwers DJ *et al.* *In-vitro* susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands. *Equine Vet J* 1993; **25**: 309–13.
25. Klein NC, Cunha BA. Tetracyclines. *Med Clin North Am* 1995; **79**: 789–801.
26. Ellison MJ. Vancomycin, metronidazole, and tetracyclines. *Clin Podiatr Med Surg* 1992; **9**: 425–42.
27. Pereira MS, Siqueira-Junior JP. Antimicrobial drug resistance in *Staphylococcus aureus* isolated from cattle in Brazil. *Lett Appl Microbiol* 1995; **20**: 391–5.
28. Amin AR, Attur MG, Thakker GD *et al.* A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. *Proc Natl Acad Sci USA* 1996; **93**: 14014–9.
29. Greenwald RA, Moak SA, Ramamurthy NS *et al.* Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. *J Rheumatol* 1992; **19**: 927–38.
30. Shlopov BV, Stuart JM, Gumanovskaya ML *et al.* Regulation of cartilage collagenase by doxycycline. *J Rheumatol* 2001; **28**: 835–42.
31. Sreekanth VR, Handa R, Wali JP *et al.* Doxycycline in the treatment of rheumatoid arthritis—a pilot study. *J Assoc Physicians India* 2000; **48**: 804–7.
32. Stone M, Fortin PR, Pacheco-Tena C *et al.* Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. *J Rheumatol* 2003; **30**: 2112–22.
33. Haerdi-Landerer MC, Suter MM, Steiner A. Intra-articular administration of doxycycline in calves. *Am J Vet Res* 2007; **68**: 1324–31.
34. Honnorat-Benabbou VC, Lebugle AA, Sallek B *et al.* Stability study of tetracyclines with respect to their use in slow release systems. *J Mater Sci Mater Med* 2001; **12**: 107–10.
35. Paquette DW. Minocycline microspheres: a complementary medical–mechanical model for the treatment of chronic periodontitis. *Compend Contin Educ Dent* 2002; **23**: 15–21.
36. Skulason S, Ingolfsson E, Kristmundsdottir T. Development of a simple HPLC method for separation of doxycycline and its degradation products. *J Pharm Biomed Anal* 2003; **33**: 667–72.
37. Greene WT. Behaviour of articular chondrocytes. *Clin Orthop* 1971; **75**: 248–60.
38. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15*. CLSI, Wayne, PA, USA, 2005.
39. Bodmeier R, Chen H, Davidson RG *et al.* Microencapsulation of antimicrobial ceftiofur drugs. *Pharm Dev Technol* 1997; **2**: 323–34.

40. Prior S, Gamazo C, Irache JM *et al.* Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. *Int J Pharm* 2000; **196**: 115–25.
41. Shameem M, Lee H, Burton K *et al.* Effect of gamma-irradiation on peptide-containing hydrophilic poly (D,L-lactide-co-glycolide) microspheres. *PDA J Pharm Sci Technol* 1999; **53**: 309–13.
42. Bittner B, Mader K, Kroll C *et al.* Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. *J Control Release* 1999; **59**: 23–32.
43. Armstrong S, Lees P. Effects of carprofen (R and S enantiomers and racemate) on the production of IL-1, IL-6 and TNF-alpha by equine chondrocytes and synoviocytes. *J Vet Pharmacol Ther* 2002; **25**: 145–53.
44. Borderie D, Hervann A, Hilliquin P *et al.* Tetracyclines inhibit nitrosothiol production by cytokine-stimulated osteoarthritic synovial cells. *Inflamm Res* 2001; **50**: 409–14.
45. Bertone AL, Palmer JL, Jones J. Synovial fluid cytokines and eicosanoids as markers of joint disease in horses. *Vet Surg* 2001; **30**: 528–38.
46. Smeets TJ, Barg EC, Kraan MC *et al.* Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. *Ann Rheum Dis* 2003; **62**: 635–8.
47. Von Rechenberg B, McIlwraith CW, Akens MK *et al.* Spontaneous production of nitric oxide (NO), prostaglandin (PGE2) and neutral metalloproteinases (NMPs) in media of explant cultures of equine synovial membrane and articular cartilage from normal and osteoarthritic joints. *Equine Vet J* 2000; **32**: 140–50.
48. Farrell AJ, Blake DR, Palmer RM *et al.* Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. *Ann Rheum Dis* 1992; **51**: 1219–22.
49. Stefanovic-Racic M, Stadler J, Georgescu HI *et al.* Nitric oxide synthesis and its regulation by rabbit synoviocytes. *J Rheumatol* 1994; **21**: 1892–8.
50. Adler H, Frech B, Thony M *et al.* Inducible nitric oxide synthase in cattle. Differential cytokine regulation of nitric oxide synthase in bovine and murine macrophages. *J Immunol* 1995; **154**: 4710–8.
51. Jauernig S, Schweighauser A, Reist M *et al.* The effects of doxycycline on nitric oxide and stromelysin production in dogs with cranial cruciate ligament rupture. *Vet Surg* 2001; **30**: 132–9.
52. Stadler J, Stefanovic-Racic M, Billiar TR *et al.* Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. *J Immunol* 1991; **147**: 3915–20.
53. Attur MG, Patel RN, Patel PD *et al.* Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. *J Immunol* 1999; **162**: 3160–7.